Pharmamarketeer
wet- en regelgeving

Pfizer’s Xeljanz jumps into ulcerative colitis fray with best-case FDA approval

4 juni 2018
FiercePharma

Xeljanz is on a roll. The Pfizer immunology blockbuster scored a big new approval in psoriatic arthritis last year, and now it has won an FDA green light to treat ulcerative colitis. Plus, the approval includes the larger 10 mg dose, despite some internal agency questions about safety.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)